Former FDA, CMS heads commend importation, government negotiation to control drug prices

In an editorial published in JAMA, former FDA Commissioner Robert Califf and former CMS Acting Administrator Andrew Slavitt endorsed a wide range of policies to reduce drug costs, including targeted importation, cutting supply chain and marketing costs, government drug-price negotiation, and creation of a value-based reimbursement system.

Califf is a professor of medicine at Duke University and adviser and advisory board member at Verily Life Sciences. Slavitt is board chair at United States of Care, a non-profit healthcare advocacy group. ...